MAPK
Le MAPK sono una famiglia di chinasi proteiche coinvolte in una varietà di processi cellulari, tra cui crescita, proliferazione, differenziazione e risposte allo stress. La via di segnalazione MAPK è composta da diversi livelli, tra cui ERK, JNK e p38 MAPK, ciascuno con ruoli distinti nella funzione cellulare. La disregolazione della segnalazione MAPK è collegata al cancro, alle malattie infiammatorie e ai disturbi metabolici. Presso CymitQuimica, offriamo una vasta gamma di inibitori e attivatori delle MAPK per supportare la tua ricerca in biologia cellulare, trasduzione del segnale e meccanismi delle malattie.
Trovati 894 prodotti di "MAPK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SOS1-IN-15
CAS:<p>SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer.</p>Formula:C28H27F3N6O2Purezza:98.32%Colore e forma:SolidPeso molecolare:536.548RMC-0331
CAS:RMC-0331 (RM-023) is an oral SOS1 inhibitor with potential to block RAS activation and anticancer properties.Formula:C22H25ClF3N5O3Purezza:97.84%Colore e forma:SolidPeso molecolare:499.91EO-1606
CAS:<p>EO-1606 is a p38MAP kinase inhibitor with anti-inflammatory activity and may be used in studies of Alzheimer;s disease and dermatitis.</p>Formula:C21H17ClFNOPurezza:98.28% - 98.84%Colore e forma:SolidPeso molecolare:353.82p38 MAPK Inhibitor
CAS:<p>p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.</p>Formula:C20H13ClFN3OPurezza:99.91%Colore e forma:SolidPeso molecolare:365.79MKK7-COV-9
CAS:MKK7-COV-9 is an MKK7 inhibitor that inhibits MKK7-induced protein-protein interactions and interrupts the activation of primary B cells in response to LPS.Formula:C18H16N4O2Purezza:99.73% - 99.83%Colore e forma:SolidPeso molecolare:320.35AKP-001
CAS:AKP-001 is a selective inhibitor of MAPK of the p38α isoform and is used in the study of immune and digestive disorders.Formula:C21H13ClF2N4O2Purezza:99.50% - 99.92%Colore e forma:SolidPeso molecolare:426.8Cot inhibitor-1
CAS:Cot inhibitor-1 selectively blocks Tpl2 kinase, reducing TNF-alpha in blood (IC50: 5.7 nM). It may treat arthritis, IBD, and certain cancers.Formula:C27H27Cl2FN8Purezza:98.87%Colore e forma:SolidPeso molecolare:553.46JNK-IN-11
CAS:JNK-IN-11 inhibits JNK1/2/3 (IC50: 2.2/21.4/1.8 μM); promising for Alzheimer's/Parkinson's research.Formula:C12H11NO3S2Purezza:98.82%Colore e forma:SolidPeso molecolare:281.35JNK3 inhibitor-1
CAS:JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.Formula:C21H17ClFN5O2SColore e forma:SolidPeso molecolare:457.91TC13172
CAS:TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.Formula:C17H16N4O5SPurezza:98%Colore e forma:SolidPeso molecolare:388.4HPK1-IN-9
CAS:HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)Formula:C30H33N7O2Colore e forma:SolidPeso molecolare:523.63TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Formula:C30H38N6OPurezza:98%Colore e forma:SolidPeso molecolare:498.66ARS-1323
CAS:ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.Formula:C21H17ClF2N4O2Purezza:99.53%Colore e forma:SolidPeso molecolare:430.84ARS-1323-alkyne
CAS:ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.Formula:C28H27ClF2N6O3Purezza:98.00% - 99%Colore e forma:SolidPeso molecolare:569KRAS G12C inhibitor 17
CAS:KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.Formula:C24H20ClF2N3O3Purezza:98%Colore e forma:SolidPeso molecolare:471.88SB-682330A
CAS:SB-682330A is a Raf kinase inhibitor.Formula:C28H27N3O3Colore e forma:SolidPeso molecolare:453.53pan-KRAS-IN-2
CAS:Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12DFormula:C34H34F2N4O3Purezza:98%Colore e forma:SolidPeso molecolare:584.66KRAS G12D modulator-1
CAS:KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and isFormula:C30H36FN5O4Purezza:98%Colore e forma:SolidPeso molecolare:549.64KRAS G12C inhibitor 58
CAS:KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].Formula:C51H64ClF4N9O8SPurezza:98%Colore e forma:SolidPeso molecolare:1074.62KRAS G12C inhibitor 16
CAS:KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.Formula:C24H21ClFN3O3Purezza:97.84%Colore e forma:SolidPeso molecolare:453.89DT-061
CAS:DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.Formula:C25H23F3N2O5SPurezza:98%Colore e forma:SolidPeso molecolare:520.52KRAS G12C inhibitor 59
CAS:KRAS G12C Inhibitor 59 is a compound with anticancer properties.Formula:C32H39F6N7O5Purezza:98%Colore e forma:SolidPeso molecolare:715.69BI-0474
CAS:<p>BI-0474: KRASG12C inhibitor, IC50=7.0 nM, blocks GDP-KRAS/SOS1, anti-tumor in NCI-H358 cells & lung cancer model, for cancer research.</p>Formula:C30H37N9O2SPurezza:99.61%Colore e forma:SolidPeso molecolare:587.74Rac1-IN-3
CAS:Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].Formula:C21H23N7O2Purezza:98%Colore e forma:SolidPeso molecolare:405.45HPK1-IN-35
CAS:HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM.Formula:C30H32N8O3SColore e forma:SolidPeso molecolare:584.69AZ-TAK1
CAS:"AZ-Tak1 inhibits TAK1 kinase (IC50=0.009mM), reduces p38/ERK levels, and induces apoptosis in Mino, SP53, Jeko cells with increasing efficacy at 0.1-0.5mM."Formula:C25H28FN7O2Colore e forma:SolidPeso molecolare:477.53SB 203580 sulfone
CAS:<p>SB 203580 sulfone, an analog of the p38 MAP kinase inhibitor SB 203580, inhibits IL-1 production in monocytes and binds competitively with CSAID binding proteins (CSBP), inhibiting stress response signaling. It exhibits an IC50 of 0.2 μM for IL-1 inhibition and 0.03 μM for CSBP-mediated signaling inhibition [1].</p>Formula:C21H16FN3O2SColore e forma:SolidPeso molecolare:393.43pan-KRAS-IN-3
CAS:Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].Formula:C33H32F3N5O2Purezza:98%Colore e forma:SolidPeso molecolare:587.63K-Ras G12C-IN-1
CAS:K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.Formula:C22H23Cl2N3O3Colore e forma:SolidPeso molecolare:448.34SKF-86002 dihydrochloride
CAS:<p>p38 MAP kinase inhibitor</p>Formula:C16H14Cl2FN3SPurezza:98%Colore e forma:SolidPeso molecolare:370.27pan-KRAS-IN-4
CAS:Pan-KRAS-IN-4 (compound 5) is a potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for Kras G12C and 0.19 nM for Kras G12V [1].Formula:C36H34F2N6O3Purezza:98%Colore e forma:SolidPeso molecolare:636.69KRAS G12C inhibitor 5
CAS:KRAS G12C inhibitor 5 is a KRas G12C inhibitor.Formula:C32H37N7O2Purezza:98%Colore e forma:SolidPeso molecolare:551.68KRAS G12C inhibitor 34
CAS:KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.Formula:C32H32ClN5O3Colore e forma:SolidPeso molecolare:570.08TNIK&MAP4K4-IN-1
CAS:TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor targeting TNIK and MAP4K4/HGK, exhibiting IC50 values of 1.29 nM and <10 nM, respectively, in humanFormula:C25H23FN4O3Colore e forma:SolidPeso molecolare:446.47KRas G12C inhibitor 1
CAS:KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.Formula:C31H38N6O3Purezza:98%Colore e forma:SolidPeso molecolare:542.67(aS)-PH-797804
CAS:(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating inhibitory concentration (IC50) values of 26 nM for p38α and 102 nM for p38β. This compound exhibits anti-inflammatory activity [1] [2].Formula:C22H19BrF2N2O3Colore e forma:SolidPeso molecolare:477.3Deltasonamide 1
CAS:Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.Formula:C30H39ClN6O4S2Colore e forma:SolidPeso molecolare:647.25ERK1/2 inhibitor 8
CAS:ERK1/2 inhibitor 8 is a potent inhibitor of ERK that acts on ERK2 (IC50: 0.48 nM).Formula:C23H20ClN7O2SColore e forma:SolidPeso molecolare:493.97PROTAC KRAS G12C degrader-3
CAS:PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].Formula:C63H75ClN14O6Purezza:98%Colore e forma:SolidPeso molecolare:1159.81HPK1-IN-37
CAS:HPK1-IN-37 (compound A85), with an IC50 value of 3.7 nM, is a potent inhibitor of HPK1.Formula:C27H35N7O4Colore e forma:SolidPeso molecolare:521.61RPR203494
CAS:RPR203494 is a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.Formula:C26H29FN6O4Colore e forma:SolidPeso molecolare:508.54KRAS G12C inhibitor 13
CAS:<p>KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .</p>Formula:C40H46F3N7O4Purezza:98%Colore e forma:SolidPeso molecolare:745.83KRAS G12C inhibitor 14
CAS:KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor with an IC 50 of 18 nM [1].Formula:C24H19ClF2N4O3Purezza:98%Colore e forma:SolidPeso molecolare:484.88AZD4747
CAS:<p>AZD4747 is an inhibitor of the mutant GTPase KRASG12C that hasial antitumor activity for the study of pancreatic and colorectal adenocarcinoma.</p>Formula:C24H22ClFN2O3Purezza:99.36%Colore e forma:SolidPeso molecolare:440.89ERK Inhibitor II (Negative control)
CAS:ERK Inhibitor II, a control, blocks ERK and insulin receptor activation, aiding diabetes research.Formula:C18H12N6OColore e forma:SolidPeso molecolare:328.33RAF mutant-IN-1
CAS:RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).Formula:C23H18Cl3FN6O2SPurezza:98%Colore e forma:SolidPeso molecolare:567.85GSK1790627
CAS:GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].Formula:C24H21FIN5O3Colore e forma:SolidPeso molecolare:573.36KRAS inhibitor-11
KRAS inhibitor-11 is a KRAS inhibitor .Formula:C29H47N9O6Colore e forma:SolidPeso molecolare:617.74MNK inhibitor 9
CAS:<p>MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.</p>Formula:C25H29N9OColore e forma:SolidPeso molecolare:471.56XRP44X
CAS:XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.Formula:C21H21ClN4OPurezza:99.67%Colore e forma:SolidPeso molecolare:380.87HPK1-IN-12
CAS:HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.Formula:C25H24FN5O2Colore e forma:SolidPeso molecolare:445.49GNE 220
CAS:GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).Formula:C25H26N8Purezza:98%Colore e forma:SolidPeso molecolare:438.53FGTI-2734
CAS:<p>FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.</p>Formula:C26H31FN6O2SPurezza:99.69%Colore e forma:SolidPeso molecolare:510.63KRAS G12C inhibitor 40
CAS:KRAS G12C inhibitor 40 targets KRAS G12C in cancer research (WO2021129824A1, compound 70).Formula:C34H36ClFN10O2Colore e forma:SolidPeso molecolare:671.17K-Ras G12C-IN-2
CAS:K-Ras G12C-IN-2 is a covalent kras g12c inhibitor.Formula:C21H27ClN4O3Purezza:98%Colore e forma:SolidPeso molecolare:418.92ERK1/2 inhibitor 5
CAS:ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.Formula:C28H32ClFN6O5Colore e forma:SolidPeso molecolare:587.04Ilaprazole sodium hydrate
CAS:Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.Formula:C19H21N4NaO4SPurezza:99.2%Colore e forma:SolidPeso molecolare:424.45CXJ-2
CAS:CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.Formula:C55H87N15O22Purezza:98%Colore e forma:SolidPeso molecolare:1310.37ERK-IN-2 free base
CAS:ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.Formula:C16H17N5O2Colore e forma:SolidPeso molecolare:311.34FGTI-2734 mesylate (1247018-19-4 free base)
CAS:FGTI-2734 mesylate hinders KRAS, overcoming resistance and targeting pancreatic tumors; inhibits FT and GGT with IC50s of 250 nM, 520 nM.Formula:C27H35FN6O5S2Purezza:98%Colore e forma:SolidPeso molecolare:606.73GNE 220 hydrochloride
CAS:<p>GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Formula:C25H27ClN8Colore e forma:SolidPeso molecolare:474.99SOS1/KRAS-IN-1
CAS:SOS1/KRAS-IN-1 (Compound 2) serves as an inhibitor of SOS1/KRAS, with potential application in the study of diseases mediated by SOS1/KRAS [1].Formula:C24H26F3N5OPurezza:98%Colore e forma:SolidPeso molecolare:457.49HPK1-IN-10
CAS:HPK1-IN-10 inhibits HPK1, a MAP4K kinase from progenitor cells, with potential in treating HPK1 diseases, detailed in patent WO2021213317A1.Formula:C31H34N6O2Colore e forma:SolidPeso molecolare:522.64KRAS G12C inhibitor 51
CAS:KRAS G12C inhibitor 51 is a KRAS G12C inhibitor.Formula:C33H35FN6O3Colore e forma:SolidPeso molecolare:582.67Pan-RAF kinase inhibitor 1
CAS:Potent Pan-RAF inhibitor 1 targets RAF/MAPK pathway, curbing RAS-mutated cancer cell growth. (Patent WO2021110141A1, compound 16B)Formula:C26H24F3N3O4Colore e forma:SolidPeso molecolare:499.48KRAS G12C inhibitor 30
CAS:KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.Formula:C25H22ClFN6O3Colore e forma:SolidPeso molecolare:508.93Glecirasib
CAS:Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signalingFormula:C31H26ClF4N7O2Purezza:99.7% - >99.99%Colore e forma:SolidPeso molecolare:640.03HPK1-IN-13
CAS:HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.Formula:C25H24FN5O2Colore e forma:SolidPeso molecolare:445.49KRAS G12C inhibitor 32
CAS:KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].Formula:C29H30Cl3FN6O3Purezza:98%Colore e forma:SolidPeso molecolare:635.94HPK1-IN-11
CAS:HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.Formula:C27H25N5O2Colore e forma:SolidPeso molecolare:451.52KRAS G12C inhibitor 53
CAS:KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.Formula:C21H14ClF2N5O2Colore e forma:SolidPeso molecolare:441.82HPK1-IN-33
CAS:HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.Formula:C18H16ClFN6Colore e forma:SolidPeso molecolare:370.81KRAS G12C inhibitor 25
CAS:KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).Formula:C32H41N7O2Colore e forma:SolidPeso molecolare:555.71KRAS G12C inhibitor 21
CAS:KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.Formula:C34H30ClN3O4Colore e forma:SolidPeso molecolare:580.07KRAS G12C inhibitor 35
CAS:KRAS G12C inhibitor 35 targets KRAS G12C in cancer research (CN112920183A, compound 3).Formula:C31H27ClF2N6O3Colore e forma:SolidPeso molecolare:605.03SOS1-IN-4
CAS:SOS1-IN-4 is a potent inhibitor of SOS1 (IC50: 56 nM) and can be used in the study of KRAS-C12C/SOS1 interactions.Formula:C24H29F2N4O2PColore e forma:SolidPeso molecolare:474.48ZG1077
CAS:ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.Formula:C33H33F2N5O5SColore e forma:SolidPeso molecolare:649.71HPK1-IN-27
CAS:HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.Formula:C26H23F3N4O4Colore e forma:SolidPeso molecolare:512.48KRAS inhibitor-18
CAS:KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.Formula:C20H15ClF3N3O2SColore e forma:SolidPeso molecolare:453.87SOS1-IN-16
CAS:SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 ofFormula:C30H31F3N4O3Purezza:98%Colore e forma:SolidPeso molecolare:552.59CMP3a
CAS:CMP3a, a NEK2 inhibitor, hinders GBM in mice and enhances radiotherapy by disrupting EZH2.Formula:C28H27F3N6O2SColore e forma:SolidPeso molecolare:568.61SOS1-IN-14
CAS:SOS1-IN-14 是选择性的、有效的、口服具有活力的 SOS1 抑制剂 (IC50: 3.9 nM)。SOS1-IN-14 能够利用 P-糖蛋白介导的外排机制在肠道内被吸收。SOS1-IN-14 能够用于 KRAS 突变的癌症的研究，且抑瘤效果比 BI-3406 好。Formula:C29H29F3N6O2Colore e forma:SolidPeso molecolare:550.57GGTI-297
CAS:GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).Formula:C26H31N3O3SColore e forma:SolidPeso molecolare:465.61ERK1/2 inhibitor 7
CAS:ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).Formula:C23H22FN7OSColore e forma:SolidPeso molecolare:463.53KRAS G12C mutant protein inhibitor A-1
CAS:KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.Formula:C31H26ClF4N7O2Colore e forma:SolidPeso molecolare:640.03SOS1-IN-8
CAS:SOS1-IN-8 is an inhibitor of SOS1 and acts on SOS1-G12D (IC50: 11.6 nM) and SOS1-G12V (IC50: 40.7 nM).Formula:C24H26F3N3O4Colore e forma:SolidPeso molecolare:477.48Ras inhibitor 134
CAS:Ras inhibitor 134 can be used in studies about Ras.Formula:C23H21ClFN5O3Colore e forma:SoildPeso molecolare:469.9KRAS inhibitor-12
CAS:KRAS inhibitor-12 blocks KRAS G12C (IC50: 0.537 μM) and p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancer study.Formula:C19H16Cl2FN5OSColore e forma:SolidPeso molecolare:452.33SOS1-IN-5
CAS:<p>SOS1-IN-5, a potent pyrimidine inhibitor, disrupts RAS-SOS1, blocking KRAS activation.</p>Formula:C26H31F3N4O5Colore e forma:SolidPeso molecolare:536.54KRAS G12C inhibitor 49
CAS:KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.Formula:C31H31ClN6O3Colore e forma:SolidPeso molecolare:571.07B-Raf IN 5
CAS:B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR.Formula:C23H18ClF3N6O3S2Colore e forma:SolidPeso molecolare:583.01KRAS G12C inhibitor 41
CAS:KRAS G12C inhibitor 41 targets a key signaling protein, potentially aiding cancer research.Formula:C36H37ClFN9O2Colore e forma:SolidPeso molecolare:682.19SHP2-IN-22
CAS:<p>SHP2-IN-22, a potent SHP2 allosteric inhibitor, exhibits an IC50 value of 17.7 nM and effectively suppresses proliferation, migration, and invasion in MIA PaCa-</p>Formula:C23H22Cl2N8OColore e forma:SolidPeso molecolare:497.38CHI-000-667
CAS:<p>CHI-000-667 can be used in studies about Ras.</p>Formula:C21H16ClNO4SColore e forma:SolidPeso molecolare:413.87KRAS G12C inhibitor 28
CAS:KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (Formula:C33H36F2N5O4PColore e forma:SolidPeso molecolare:635.64ARQ-736
CAS:ARQ 736 effectively targets and inhibits BRAF, crucial in MAPK pathway, beneficial for treating melanomas and certain colon cancers.Formula:C25H25N8Na2O8PSColore e forma:SolidPeso molecolare:674.54Kras binder 12
CAS:Kras binder 12 can be used in studies about Ras.Formula:C29H47N9O6Colore e forma:SoildPeso molecolare:617.74KRAS degrader-1
CAS:<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Formula:C55H57Br2ClFIN8O7Colore e forma:SolidPeso molecolare:1283.25KRAS inhibitor FB9
CAS:KRAS inhibitor FB9 can be used in studies about Ras.Formula:C23H21ClF4N2O5Colore e forma:SolidPeso molecolare:516.87KRAS G12D mutation regulator 4
CAS:KRAS G12D mutation regulator 4 can be used in studies about Ras.Formula:C33H33FN6O2Colore e forma:SolidPeso molecolare:564.65SOS1-IN-7
CAS:SOS1-IN-7 (compound 18-p1) is a potent inhibitor of SOS1 and acts on SOS1-G12D (IC50: 20 nM) and SOS1-G12V (IC50: 67 nM).Formula:C23H25F3N4O3Colore e forma:SolidPeso molecolare:462.46KRAS inhibitor-14
CAS:<p>KRAS inhibitor-14 targets G12C (IC50: 0.249 μM) and inhibits p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancers.</p>Formula:C20H15Cl3FN3O2SColore e forma:SolidPeso molecolare:486.77KRAS G12C inhibitor 1R
CAS:KRAS G12C inhibitor 1R can be used in studies about Ras.Formula:C31H36ClFN6O2Colore e forma:SoildPeso molecolare:579.11SOS1-IN-13
CAS:SOS1-IN-13 inhibits SOS1 (IC50: 6.5 nM) and pERK (327 nM); potential in cancer research.Formula:C21H22F3N3O2Colore e forma:SolidPeso molecolare:405.41HPK1 antagonist-1
CAS:HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].Formula:C28H29FN6O2Colore e forma:SolidPeso molecolare:500.57AMG-548 hydrochloride (864249-60-5 free base)
AMG-548 hydrochloride is an orally active and selective p38α inhibitor (Ki: 0.5 nM) and shows slightly selective over p38β (Ki: 36 nM) and >1000 fold selectiveFormula:C29H28ClN5OPurezza:98%Colore e forma:SolidPeso molecolare:498.02DL-threo dihydrosphingosine
CAS:DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.Formula:C18H39NO2Colore e forma:SolidPeso molecolare:301.51Inflachromene
CAS:Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.Formula:C21H19N3O4Purezza:97.36% - 99.88%Colore e forma:SolidPeso molecolare:377.39L 731734
CAS:<p>L 731734 is a farnesyltransferase inhibitor.</p>Formula:C19H38N4O3SColore e forma:SolidPeso molecolare:402.6(R)-BDP9066
CAS:(R)-BDP9066 blocks MRCK to curb cancer cell spread, aiding research on diseases like cancer.Formula:C20H24N6Colore e forma:SolidPeso molecolare:348.44BDP8900
CAS:BDP8900: potent, selective MRCK inhibitor; alters cancer cell shape, reduces mobility and invasion.Formula:C19H23N5SColore e forma:SolidPeso molecolare:353.48RO4927350
CAS:RO4927350 is a potent, selective MEK1/2 inhibitor, blocking MAPK pathway in vitro/vivo and showing notable antitumor effects.Formula:C27H28N4O6SColore e forma:SolidPeso molecolare:536.6JNK3 inhibitor-3
CAS:JNK3 Inhibitor-3 selectively blocks JNK3 (>4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.Formula:C26H25N7O2Purezza:98%Colore e forma:SolidPeso molecolare:467.52MEK-IN-6 hydrate
CAS:MEK-IN-6 hydrate (compound 69), a MEK inhibitor, exhibits an IC50 value of 2 nM in A375 cells [1].Formula:C18H22FN3O5SPurezza:98%Colore e forma:SolidPeso molecolare:411.45MEK-IN-6
CAS:MEK-IN-6 (Example 69), a potent MEK inhibitor, effectively inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells, with an IC50 of 2 nM, making itFormula:C18H20FN3O4SPurezza:98%Colore e forma:SolidPeso molecolare:393.43AMG-548 dihydrochloride (864249-60-5 free base)
AMG-548 dihydrochloride: oral p38α inhibitor, Ki: 0.5 nM; less so for p38β, Ki: 36 nM; >> p38γ/δ; blocks LPS-induced TNFα, IC50: 3 nM.Formula:C29H29Cl2N5OPurezza:98%Colore e forma:SolidPeso molecolare:534.48(R)-VX-11e
CAS:(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.Formula:C24H20Cl2FN5O2Purezza:98.73%Colore e forma:SolidPeso molecolare:500.35Cobimetinib racemate
CAS:Cobimetinib racemate (Cobimetinib (racemate)) (GDC-0973 racemate) is a selective inhibitor of MEK.Cobimetinib racemate is also known as a mitogen-activatedFormula:C21H21F3IN3O2Purezza:98.00% - 99.71%Colore e forma:SolidPeso molecolare:531.31Uplarafenib
CAS:Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.Formula:C22H21F3N4O4SPurezza:99.98%Colore e forma:SolidPeso molecolare:494.49MS934
CAS:<p>MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.</p>Formula:C52H69F3IN7O6SPurezza:98%Colore e forma:SolidPeso molecolare:1104.11Org OD 02-0
CAS:10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activateFormula:C22H30O2Purezza:98%Colore e forma:SolidPeso molecolare:326.47B-Raf IN 15
CAS:<p>B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.</p>Formula:C19H15N3OSPurezza:98%Colore e forma:SolidPeso molecolare:333.41KRAS G12C inhibitor 61
CAS:KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.Formula:C31H33ClFN7O2Purezza:98%Colore e forma:SolidPeso molecolare:590.09Laxiflorin B
CAS:Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].Formula:C20H24O5Purezza:98%Colore e forma:SolidPeso molecolare:344.4p38 Kinase inhibitor 4
CAS:Compound 135, also known as p38 Kinase Inhibitor 4, is a potent inhibitor of p38 [1].Formula:C12H9Cl2N3OPurezza:98%Colore e forma:SolidPeso molecolare:282.13B-Raf IN 16
CAS:<p>B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.</p>Formula:C20H19N5O3SPurezza:99.31% - 99.78%Colore e forma:SolidPeso molecolare:409.46ERK1/2 inhibitor 9
CAS:ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates theFormula:C31H32ClN7O3Purezza:98%Colore e forma:SolidPeso molecolare:586.08Raf inhibitor 3
CAS:Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].Formula:C18H19FN8O2SPurezza:98%Colore e forma:SolidPeso molecolare:430.46Exarafenib
CAS:Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.Formula:C26H34F3N5O3Purezza:98.36% - 99.84%Colore e forma:SolidPeso molecolare:521.58BI-2493
CAS:BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.Formula:C24H27N7OSPurezza:97.74% - 99.88%Colore e forma:SoildPeso molecolare:461.58Kras4B G12D-IN-1
CAS:Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.Formula:C16H21ClN2O4SPurezza:99.75%Colore e forma:SolidPeso molecolare:372.87HG6-64-1
CAS:HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.Formula:C32H34F3N5O2Purezza:99.89%Colore e forma:SolidPeso molecolare:577.64ZYF0033
CAS:ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.Formula:C26H30N4O2SPurezza:99.70%Colore e forma:SolidPeso molecolare:462.61MK-8353
CAS:MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)Formula:C37H41N9O3SPurezza:96.15% - 97.19%Colore e forma:SolidPeso molecolare:691.84Pan-RAS-IN-1
CAS:Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.Formula:C36H41Cl2F3N6O2Purezza:99.77%Colore e forma:SolidPeso molecolare:717.65Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Formula:C32H31ClF2N6O4Purezza:98.69%Colore e forma:SolidPeso molecolare:637.08PAT-IN-1
CAS:PAT-IN-1, a protein acyl transferases (PAT) inhibitor, competitively inhibits Erf2 autopalmitoylation (WO2017011518A1; compound 13) [1].Formula:C45H68N4OColore e forma:SolidPeso molecolare:681.05KRAS ligand 3
CAS:KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].Formula:C24H28F3N5Colore e forma:SolidPeso molecolare:443.51KRAS G12D inhibitor 19
CAS:KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.Formula:C35H34F2N6O3Colore e forma:SolidPeso molecolare:624.68KRASG12C IN-12
CAS:KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.Formula:C29H39N5O6S2Colore e forma:SolidPeso molecolare:617.78KRAS inhibitor-32
CAS:KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.Formula:C29H35FN10OS2Colore e forma:SolidPeso molecolare:622.78LZTR1-KRAS modulator 1
CAS:LZTR1-KRAS modulator 1 is a regulator of the KRAS-LZTR1 interaction, enhancing the recruitment of the LZTR1-KRAS complex.Formula:C11H11Cl2NOColore e forma:SolidPeso molecolare:244.12KRAS G12D inhibitor 9
CAS:KRAS G12D inhibitor 9 targets RAS protein, key in growth, showing promise against KRAS G12D cancer.Formula:C33H43N7O2Colore e forma:SolidPeso molecolare:569.74Refametinib R enantiomer
CAS:<p>Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used</p>Formula:C19H20F3IN2O5SPurezza:99.86%Colore e forma:SolidPeso molecolare:572.34KRAS G12D inhibitor 11
CAS:KRAS G12D inhibitor 11 targets KRAS G12D in cancer research (patent WO2021108683A1, compound 52).Formula:C29H38BN5O3Colore e forma:SolidPeso molecolare:515.45KRAS inhibitor-34
CAS:KRAS inhibitor-34 (compound 27) is a KRAS inhibitor with an IC50 of 6.4 nM and is utilized in oncological research.Formula:C43H41F3N6O3Colore e forma:SolidPeso molecolare:746.82pan-KRAS degrader 1
CAS:<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Formula:C22H26N8OSColore e forma:SolidPeso molecolare:450.56KRAS G12D inhibitor 16
CAS:<p>KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.</p>Formula:C32H39IN6O3Colore e forma:SolidPeso molecolare:682.59MRTX849 acid
CAS:MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.Formula:C34H37ClFN7O4Colore e forma:SolidPeso molecolare:662.16KRASG12C IN-13
CAS:KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.Formula:C22H17ClF2N6OSColore e forma:SolidPeso molecolare:486.93KRAS G12C inhibitor 33
CAS:KRAS G12C inhibitor 33 is a KRAS G12C inhibitor that can be used to study cancer.Formula:C30H33N7O3Colore e forma:SolidPeso molecolare:539.63KRAS ligand 5
CAS:KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.Formula:C30H30F2N4O4Colore e forma:SolidPeso molecolare:548.58MK2-IN-4
CAS:MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.Formula:C25H24N4O2Colore e forma:SolidPeso molecolare:412.48KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Formula:C14H13NO4Colore e forma:SolidPeso molecolare:259.26AZD4625
AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.Formula:C24H21ClF2N4O3Colore e forma:SolidPeso molecolare:486.9KRAS G12C inhibitor 46
CAS:KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.Formula:C32H33F2N7O2Colore e forma:SolidPeso molecolare:585.65KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Formula:C38H32F4N6O3SColore e forma:SolidPeso molecolare:728.76KRAS inhibitor-21
CAS:KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.Formula:C33H41N5O3Colore e forma:SolidPeso molecolare:555.71Everafenib
Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.Formula:C20H23ClFN5O2S2Colore e forma:SolidPeso molecolare:484.01G12Si-1
G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.Formula:C29H32ClN5O3Colore e forma:SolidPeso molecolare:534.05PF-03715455
CAS:PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.Formula:C35H34ClN7O3S2Purezza:98%Colore e forma:SolidPeso molecolare:700.27MAP855
CAS:MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.Formula:C28H23ClF2N6O3Colore e forma:SolidPeso molecolare:564.97PS-166276
CAS:PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.Formula:C20H30N8OColore e forma:SolidPeso molecolare:398.51Luvometinib
CAS:Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.Formula:C26H22F2IN5O4SColore e forma:SolidPeso molecolare:665.45ZCL279
CAS:ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.Formula:C24H18N2O7S2Colore e forma:SolidPeso molecolare:510.539KRAS G12D inhibitor 28
CAS:<p>KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.</p>Formula:C35H32Cl2FN5OColore e forma:SolidPeso molecolare:628.57MLKL-IN-1
MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.Formula:C19H20N2O3Colore e forma:SolidPeso molecolare:324.37INCB159020
CAS:INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.Formula:C37H35ClFN7O2Colore e forma:SolidPeso molecolare:664.171GDC-6036-NH
CAS:GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.Formula:C26H30ClF4N7OPurezza:99.84%Colore e forma:SolidPeso molecolare:568.01KRAS inhibitor-13
CAS:KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.Formula:C25H19ClFN3O2SColore e forma:SolidPeso molecolare:479.95AMG-548 hydrochloride
AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.Formula:C29H28ClN5OColore e forma:SolidPeso molecolare:498.02SHR902275
CAS:SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.Formula:C26H23F3N4O4Colore e forma:SolidPeso molecolare:512.48ERK1/2 inhibitor 6
CAS:ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.Formula:C27H29ClFN7O5Colore e forma:SolidPeso molecolare:586.01RSK4-IN-1
CAS:RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.Formula:C19H20F2N4O3Colore e forma:SolidPeso molecolare:390.38HPK1-IN-3
HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.Formula:C23H22F4N6O2Colore e forma:SolidPeso molecolare:490.45SOS1-IN-9
SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).Formula:C22H28F3N5OColore e forma:SolidPeso molecolare:435.49KRAS inhibitor-41
CAS:<p>KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.</p>Formula:C30H37FN10OSColore e forma:SolidPeso molecolare:604.745KRAS G12C inhibitor 44
KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.Formula:C31H36ClFN6O2Colore e forma:SolidPeso molecolare:579.11Rho GTPase inhibitor 1
CAS:Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.Formula:C18H16N2OColore e forma:SolidPeso molecolare:276.33MEK4 inhibitor-2
CAS:MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.Formula:C20H15FN4O3SColore e forma:SolidPeso molecolare:410.42EBI-907
CAS:EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.Formula:C23H21ClF2N4O3SColore e forma:SolidPeso molecolare:506.95Fulzerasib
CAS:<p>Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutant</p>Formula:C32H30ClFN6O4Purezza:98.04%Colore e forma:SolidPeso molecolare:617.07SOS1-IN-6
CAS:SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).Formula:C26H28F3N3O2Colore e forma:SolidPeso molecolare:471.51HPK1-IN-21
HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.Formula:C22H25ClFN5O2Colore e forma:SolidPeso molecolare:445.92SOS2 ligand 1
CAS:SOS2 ligand 1 (compound 2) is a selective ligand for son of sevenless 2 (SOS2), exhibiting a KD value of 4.6 µM.Formula:C19H21N5OColore e forma:SolidPeso molecolare:335.403LSN3074753
CAS:<p>LSN3074753, a derivative of LY3009120, acts as a pan-RAF and Raf dimer inhibitor. This compound exhibits inhibitory activity against tumor cells driven by either BRAF monomers or RAF dimers, particularly in the activation of the MAPK pathway, including colorectal cancers with BRAF or KRAS mutations. When combined with Cetuximab, LSN3074753 demonstrates additive and synergistic effects in colorectal cancer PDX models, especially in those harboring KRAS or BRAF mutations.</p>Formula:C24H30FN5O2Colore e forma:SolidPeso molecolare:439.53MEK1/2-IN-2
MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.Formula:C28H22ClFN6OColore e forma:SolidPeso molecolare:512.97HPK1-IN-16
CAS:HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.Formula:C28H27FN4OColore e forma:SolidPeso molecolare:454.54HPK1-IN-31
HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .Formula:C30H33N7O3Colore e forma:SolidPeso molecolare:539.63AMG-548 dihydrochloride
AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.Formula:C29H29Cl2N5OColore e forma:SolidPeso molecolare:534.48TH-Z816
CAS:TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].Formula:C29H38N6OColore e forma:SolidPeso molecolare:486.65Famlasertib
CAS:Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.Formula:C26H27ClN4OColore e forma:SolidPeso molecolare:446.972KRASG12D-IN-3-d3
CAS:KRASG12D-IN-3-d3 is the deuterium labeled KRASG12D-IN-3. KRASG12D-IN-3 (compound Z1084) is a KRASG12D inhibitor with oral bioactivity that can effectively inhibit the growth of tumor cells AGS and AsPC-1, with IC50 values of 0.38 nM and 1.23 nM, respectively.Formula:C31H27D3ClF6N7O2Colore e forma:SoildPeso molecolare:685.08pan-KRAS-IN-6
CAS:<p>Pan-KRAS-IN-6 (compound 12) is a potent pan-KRAS inhibitor, with IC50 values of 9.79 nM for Kras G12D and 6.03 nM for Kras G12V.</p>Formula:C29H30ClF3N6O3SColore e forma:SolidPeso molecolare:635.10COTI-219
CAS:COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].Formula:C17H18N6SColore e forma:SolidPeso molecolare:338.43pan-Raf/RTK inhibitor 1
CAS:<p>Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.</p>Formula:C29H28F3N7O3Colore e forma:SolidPeso molecolare:579.573BBO-8520
CAS:BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.Formula:C35H33F6N7O2SPurezza:97.879%Colore e forma:SolidPeso molecolare:729.74MCB-22-174
CAS:MCB-22-174 is a potent agonist of Piezo1 with an EC50 value of 6.28 µM. It activates Ca2+-related extracellular signal-regulated kinase and calcium-calmodulin (CaM)-dependent protein kinase II (CaMKII) pathways, and it promotes mesenchymal stem cell osteogenic differentiation, indicating its potential application in the study of disuse osteoporosis (OP).Formula:C16H14DCl2N5OS2Peso molecolare:429.37K-Ras-IN-4
CAS:K-Ras-IN-4 (compound CP163) is an inhibitor of K-Ras.Formula:C31H28F4N6O3SColore e forma:SolidPeso molecolare:640.65BMS-214662
CAS:BMS-214662 is a selective farnesyl transferase inhibitor with anti-tumor activity, used in research on pancreatic cancer, head and neck cancer, and lung cancer.Formula:C25H23N5O2S2Purezza:99.58% - 99.58%Colore e forma:SolidPeso molecolare:489.61
